DelveInsight’s, “Breast Cancer Pipeline Insight 2024” report provides comprehensive insights about 120+ Breast Cancer companies and 130+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Breast Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Breast Cancer Pipeline Outlook
Key Takeaways from the Breast Cancer Pipeline Report
- July 2024:- Eli Lilly and Company– EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy. The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).
- July 2024:- Seagen Inc.- A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination With Other Anticancer Therapies in Solid Tumors. This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they’ve grown bigger in one spot or spread to other parts of the body, they’re harder to treat. This is called advanced or metastatic cancer.
- July 2024:- MedSIR– Phase II Study for PIK3CA/PTEN-altered Advanced Metaplastic Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin. The multicenter, two-cohort, non-comparative, open-label, phase II clinical trial SABINA aims to analyze the safety and efficacy of MEN1611 in monotherapy and in combination with eribulin, a non-taxane chemotherapy agent, in Hormone Receptor (HR)-known/Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolog (PTEN)-altered, unresectable locally advanced or metastatic metaplastic breast carcinoma (MpBC) patients.
- July 2024:- Hoffmann-La Roche– A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer.
- DelveInsight’s Breast Cancer pipeline report depicts a robust space with 120+ Breast Cancer companies working to develop 130+ pipeline therapies for Breast Cancer treatment.
- The leading Breast Cancer Companies working in the market include Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
- Promising Breast Cancer Pipeline Therapies in the various stages of development includes Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
Stay ahead with the most recent pipeline outlook for Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Breast Cancer Treatment
Breast Cancer Emerging Drugs Profile
- SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a topoisomerase I payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death. It can bind to the cell membrane surface of HER2 expressing cells, and then enter the cells to reach the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells. Preclinical research results show that SHR-A1811 has good anti-tumor activity, safety, tolerability and pharmacokinetic characteristics, or can further improve drug resistance, enhance efficacy, meet clinical needs, and provide more cancer patients multiple choice. Currently, the drug is in the Phase III stage of its development for the treatment of Breast Cancer.
- HLX11: Shanghai Henlius Biotech
HLX11 is a pertuzumab biosimilar developed by Henlius independently in line with relevant regulations and guidelines on biosimilars in China and the European Union (EU), which can be potentially used in combination with trastuzumab and chemotherapy as neoadjuvant or adjuvant treatment for HER2-positive early breast cancer and in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic or unresectable locally recurrent breast cancer patients. HLX11 can specifically bind with the subdomain II of HER2 extracellular domain and inhibit the heterodimerisation of HER2 and other HER family receptors, i.e., EGFR, HER3, and HER4. This will inhibit signal transduction of relevant pathways and lead to the stop of growth and apoptosis of tumour cells. In the meantime, HLX11 can also enhance the tumour-killing activity of immune cells via antibody-dependent cell cytotoxicity. Currently, the drug is in the Phase III stage of its development for the treatment of HER2 positive Breast Cancer.
- Praluzatamab ravtansine: CytomX Therapeutics
Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. The tumor microenvironment is enriched for proteases capable of cleaving the linker, thereby releasing the mask, allowing for localized binding of CX-2009 to CD166. Currently, the drug is in the Phase II stage of its development for the treatment of Breast Cancer.
- MCLA-128: Merus N.V.
MCLA-128 is an antibody-dependent cell-mediated cytotoxicity (ADCC) -enhanced Biclonics® that utilizes Merus Dock & Block® mechanism and inhibits the neuregulin/HER3 tumor-signaling pathway in solid tumors. MCLA-128 is believed to target the HER3 signaling pathway and to overcome the resistance of tumor cells to HER2-targeted therapies using two mechanisms: blocking growth and survival pathways to stop tumor expansion and recruitment and enhancement of immune effector cells to eliminate the tumor. The therapeutic candidate is a full-length IgG bi-specific antibody that acts by targeting HER2 and HER3. It is an antibody-dependent cellular cytotoxicity (ADCC)-enhanced Biclonic, which is developed based on Biclonics ENGAGE platform. Currently the drug is in the Phase II stage of clinical trial evaluation for the treatment of Breast Cancer.
- DX126 262: Hangzhou DAC Biotech
DX-126262 is under development for the treatment of HER2-positive or HER2-mutated unresectable locally advanced or metastatic non-squamous NSCLC, Breast Cancer, breast cancer. The drug candidate is an antibody drug conjugate comprising recombinant humanized anti-Her2 monoclonal antibody conjugated to Tub-114. It is formulated as lyophilized powder and administered via intravenous route of administration. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of HER2-positive Breast Cancer.
Explore groundbreaking therapies and clinical trials in the Breast Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Breast Cancer Drugs
Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Breast Cancer Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Unveil the future of Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Breast Cancer Market Drivers and Barriers
Scope of the Breast Cancer Pipeline Report
- Coverage- Global
- Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
- Breast Cancer Pipeline Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
- Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Breast Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Breast Cancer Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Breast Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Breast Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- MCLA-128: Merus N.V.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- DX126 262: Hangzhou DAC Biotech
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- ES2B C001: ExpreS2ion Biotechnologies
- Drug profiles in the detailed report…..
- Inactive Products
- Breast Cancer Companies
- Breast Cancer Products
- Breast Cancer Unmet Needs
- Breast Cancer Market Drivers and Barriers
- Breast Cancer Future Perspectives and Conclusion
- Breast Cancer Analyst Views
- Breast Cancer Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/